| Q90292811 | A Reappraisal of Thymosin Alpha1 in Cancer Therapy |
| Q43119055 | A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B. |
| Q72467445 | A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B |
| Q61651052 | A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B |
| Q94383330 | Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia |
| Q33951469 | Antiviral chemotherapy for the treatment of hepatitis B virus infections |
| Q40915924 | Antiviral therapy of chronic hepatitis B: past, present, and future |
| Q40590020 | Autoimmune hepatitis. Evolving concepts and treatment strategies |
| Q73647722 | Biodistribution of synthetic thymosin alpha1 in the serum, urine and major organs of mice |
| Q35337473 | Chronic hepatitis B and C. What is the status of drug therapy? |
| Q34687438 | Chronic hepatitis B: current and future treatment options |
| Q40491898 | Clinical aspects of hepatitis B virus infection |
| Q45297184 | Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial |
| Q27473018 | Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. |
| Q34207450 | Current Options for the Therapy of Chronic Hepatitis B Infection |
| Q43850205 | Current status of anti-HBV chemotherapy |
| Q45155237 | Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. |
| Q34363078 | Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. |
| Q34017814 | Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study |
| Q74530408 | Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial |
| Q35967369 | Emerging treatments in chronic hepatitis B. |
| Q34519117 | Evolving therapies for the treatment of chronic hepatitis B virus infection |
| Q40499906 | Hepatic disorders. Features and appropriate management |
| Q33929132 | Hepatitis B, C & D viral markers in multitransfused thalassemic children: long-term complications and present management |
| Q47606236 | Immunotherapy for hepatitis B in the direct acting antiviral era: Reevaluating the thymosin α1 efficacy trials in the light of a combination therapy approach. |
| Q43031810 | In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. |
| Q40820452 | Infectious complications of liver disease |
| Q40979372 | Liver transplantation for hepatitis B: what have we learned and what does the future hold? |
| Q45439916 | New therapeutic strategies in the treatment of hepatitis B virus infection |
| Q41157490 | New treatments for chronic viral hepatitis B and C. |
| Q24197858 | Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection |
| Q41915848 | Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. |
| Q40931194 | Prothymosin alpha: in search of a function. |
| Q41990658 | Quantitative analysis of thymosin alpha1 in human serum by LC-MS/MS. |
| Q40441583 | Recent results in the treatment of chronic B virus hepatitis |
| Q43588381 | Restoration of immunocyte functions by thymosin alpha1 in cyclophosphamide-induced immunodeficient mice. |
| Q45789818 | THF gamma 2 stimulates cytokine release by peripheral blood mononuclear cells of patients with chronic hepatitis B virus infection |
| Q41149344 | Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations |
| Q31938458 | The conformation of peptide thymosin alpha 1 in solution and in a membrane-like environment by circular dichroism and NMR spectroscopy. A possible model for its interaction with the lymphocyte membrane. |
| Q45734557 | The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis |
| Q45855058 | Therapy for chronic hepatitis B and C infection in haemophilia |
| Q67589885 | Thymic factor X treatment of chronic hepatitis B |
| Q51064179 | Thymosin alpha-1 treatment in chronic hepatitis B. |
| Q43853513 | Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts |
| Q94401095 | Thymosin alpha1 for chronic hepatitis B |
| Q43813126 | Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study |
| Q30422105 | Thymosin α1 continues to show promise as an enhancer for vaccine response |
| Q41146904 | Thymosin-alpha 1, but not interferon-alpha, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells |
| Q44039658 | Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. |
| Q35753541 | Thymosins: chemistry and biological properties in health and disease |
| Q34289643 | Tolerability of treatments for viral hepatitis |
| Q44011412 | Treatment of chronic hepatitis D with thymus-derived polypeptide thymic humoral factor-gamma 2: a pilot study |
| Q43542079 | Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. |
| Q40408963 | Zadaxin (thymosin alpha1) for the treatment of viral hepatitis |
| Q50972793 | Zidovudine and thymus humoral factor gamma-2 in the treatment of HIV infection: preliminary clinical experience. |